Compass Therapeutics provided a general business update highlighting progress throughout its pipeline of clinical-stage drug candidates.
Key survival analyses for tovecimig in late Q1 could transform the treatment of patients with biliary tract cancer.
Preparations for the Phase 2 basket study of tovecimig in a broader set of patients with DLL4+ cancers are underway.
Compass Therapeutics is actively advancing their innovative pipeline with key milestones approaching in 2026.
CT-8371 Responses
CTX-8371 has shown promising responses in solid tumor and hematologic malignancy patients, potentially paving the way for accelerated approval in treating adult and pediatric Hodgkin Lymphoma cases.
CTX-8371 Expansions
Expansions of CTX-8371 cohorts are now available for enrollment, targeting patients with triple negative breast cancer and non-small cell lung cancer.
CTX-10726 Phase 1 Study
The onset of the Phase 1 study for CTX-10726 is anticipated in Q1 2026, with initial data anticipated in the second half of the year.
- Compass Therapeutics bolsters its senior leadership team with strategic appointments to drive the company's growth trajectory.
- Upcoming data from the Phase 2 trial of tovecimig in colorectal cancer patients will be presented at the 2026 ASCO GI Cancers Symposium, potentially signaling further clinical progress.
Compass Therapeutics is strategically positioned for significant advancements in 2026, leveraging their antibody-based therapeutics pipeline to unlock new treatment horizons and focusing on critical milestones.